Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Last Updated: Monday, March 6, 2023
Updated results on efficacy, safety, and patient-reported quality of life from the phase II ELIANA trial examining tisagenlecleucel showed no new or unexpected long-term adverse events. Median overall survival was not reached, and median event-free survival was 24 months.
Advertisement
News & Literature Highlights
